Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Moldovan SA et al.: Secretory Granule Serum Protein Signature in Resectable PDAC
PMID 41901688 | Discovery-phase proteomics case-control | 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Secretory granule lumen framing for PDAC biomarker discovery is mechanistically novel; 3-protein panel distinct from CA19-9 paradigm |
| Clinical Relevance | 7 | Resectable PDAC detection is an enormous unmet need (>80% present unresectable); AUC 0.98 is compelling but unvalidated externally |
| Population Reach | 7 | PDAC affects ~500K globally/year; resectable window is small but this is precisely where intervention changes survival |
| Implementation Speed | 2 | Discovery cohort only; feature-selection bias acknowledged; pancreatitis controls absent; 5–10+ year path to clinical use |
| Evidence Strength | 4 | n=69, single cohort, feature selection before cross-validation; AUC likely optimistic; no external or prospective validation |
Key quantitative result: AUC 0.98 (cross-validated 0.96), 83% sensitivity, 100% specificity — discovery cohort only
External validation: None; authors acknowledge CV-after-selection limitation
Main limitation: Feature selection precedes cross-validation (likely inflating AUC); no pancreatitis comparator; n=35 cases
Equity implications: PDAC disproportionately fatal in low-resource settings with limited surgical access; a serum-based test has equity upside if validated and made affordable
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 5.8
Article 2 — Wojarska M et al.: ctDNA for Melanoma Resection Assessment — Systematic Review
PMID 41901544 | Systematic review (PRISMA, 14 studies, n=1,077) | 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA in melanoma surveillance is an established concept; this review consolidates rather than discovers |
| Clinical Relevance | 7 | Post-op ctDNA monitoring is directly implementable in melanoma follow-up; recurrence prediction months before clinical detection is actionable |
| Population Reach | 6 | Melanoma incidence ~325K/year globally; post-surgical surveillance is a defined care gap |
| Implementation Speed | 6 | ctDNA assays exist commercially; main barriers are standardization and guideline integration, not technology development |
| Evidence Strength | 7 | PRISMA systematic review; 14 studies, 1,077 patients; consistent directional signal; limited by heterogeneity of assay methods |
Key quantitative result: Consistent association of post-op ctDNA persistence with recurrence across 14 studies; months-earlier detection vs clinical/imaging
External validation: Multi-study synthesis is inherently cross-cohort; heterogeneity remains a limitation
Main limitation: Assay heterogeneity; variable ctDNA detection thresholds across studies; no meta-analytic pooled effect size reported
Equity implications: ctDNA assays remain costly; may disproportionately benefit higher-income patients/health systems
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 6.3
Article 3 — Núñez-Gutiérrez K et al.: Bovine Leukemia Virus in B-ALL Bone Marrow
PMID 41902250 | Case-control | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | BLV-human leukemia link is a provocative and underexplored hypothesis; tax gene-specific association is a novel refinement |
| Clinical Relevance | 2 | No immediate clinical application; purely etiologic/hypothesis-generating; n=11 cases |
| Population Reach | 3 | B-ALL globally ~75K cases/year; geographic specificity (Colombia) and small n severely limit generalizability |
| Implementation Speed | 1 | Years of replication needed before any translational relevance |
| Evidence Strength | 3 | n=11 cases, single center, geographic confounders (agricultural exposure), classification_confidence = medium |
Key quantitative result: BLV tax gene significantly associated with B-ALL; seropositivity 18.2% in B-ALL vs 0% controls
External validation: None
Main limitation: 11 cases is critically underpowered; geographic/agricultural confounding; causality cannot be inferred
Equity implications: If BLV exposure is environmentally modifiable, findings could have public health relevance in agricultural communities
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 4 | Phase 2 composite: 2.9
Article 4 — Misterka K & Latos M: TIVAD Infections in Oncology vs Hematology
PMID 41902444 | Retrospective single-center | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Higher infection rates in hematology vs oncology is known; Gram-negative predominance in hematology has some novelty for protocol design |
| Clinical Relevance | 4 | Infection control protocols are directly actionable; hematology-specific guidance has genuine clinical value but incremental |
| Population Reach | 4 | Port-related infections affect a broad cancer population; hematology subset is smaller |
| Implementation Speed | 5 | Protocol-level changes (antibiotic prophylaxis, flushing regimens) are relatively rapid to implement |
| Evidence Strength | 3 | Retrospective single-center; sample size not reported in abstract; limited generalizability |
Key quantitative result: TIVAD infection density 3.40 vs 1.24/1000 person-days (hematology vs oncology); lymphoma 78.57% of hematology infections; 80.60% Gram-negative
External validation: None
Main limitation: Single center, Warsaw; no sample size reported; cannot assess confounders (immunosuppression depth, duration)
Equity implications: Port-related infections differentially affect patients with limited outpatient access to timely care
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 3 | Phase 2 composite: 3.8
Article 5 — Liu D et al.: ML Survival Analysis for Depression Progression in Parkinson's Disease
PMID 41902606 | Retrospective cohort, ML survival analysis (PPMI, n=496) | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Applying RSF with SHAP explainability to PD neuropsychiatric progression is novel in execution; conceptually incremental in ML-PD space |
| Clinical Relevance | 6 | Depression affects ~40% of PD patients; risk stratification could enable early intervention; tool uses routinely collected variables |
| Population Reach | 7 | ~10M people live with PD globally; neuropsychiatric comorbidity is nearly universal and undertreated |
| Implementation Speed | 5 | PPMI is a research dataset; prospective validation in diverse clinical settings needed before deployment; tool structure is EHR-compatible |
| Evidence Strength | 6 | Well-validated PPMI dataset; C-index 0.744 is respectable; limitation is single-cohort retrospective design without external validation |
Key quantitative result: RSF C-index 0.744; 10-year Kaplan-Meier separation: low-risk 7.3% progression, high-risk 36.5% progression
External validation: None; single-cohort PPMI analysis
Main limitation: Retrospective, single-dataset; no external prospective validation; PPMI is research-enriched (not real-world clinical population)
Equity implications: PPMI is predominantly White/North American; model may underperform in diverse populations; PD depression is underdiagnosed in women and minorities
Evidence Maturity: Validated → Revised: Exploratory/Validated borderline — internal validation is solid but external replication is absent
Triage score (OpenClaw): 6 | Phase 2 composite: 6.1
Article 6 — Lu H et al.: Anoikis-Related Gene Signature in Lung Squamous Cell Carcinoma
PMID 41902322 | Computational/bioinformatics; retrospective transcriptomic | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Anoikis-resistance genes as immunotherapy predictors in LUSC is a relatively novel framing; S100A7/A8/SPP1 combination has some prior support |
| Clinical Relevance | 4 | Computational only; needs wet-lab and clinical prospective validation; immunotherapy prediction utility is moderate |
| Population Reach | 6 | LUSC ~250K cases/year globally; immunotherapy selection remains imprecise |
| Implementation Speed | 2 | Pure bioinformatics; far from clinical deployment; validation pipeline needed |
| Evidence Strength | 3 | Computational retrospective; TCGA/GEO datasets; no prospective or functional validation; classification_confidence medium → conservative scoring |
Key quantitative result: Moderate OS prediction accuracy at 1/3/5 years (specific AUC values not reported in abstract)
External validation: Internal dataset split only
Main limitation: No functional validation; TCGA/GEO data are transcriptomic snapshots; no immunotherapy response outcome data confirmed
Equity implications: LUSC disproportionately affects men, smokers, and lower-SES populations who may benefit from better immunotherapy triage
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.1
Article 7 — Wang Q et al.: Immune/Molecular Profiles of Gastric Signet Ring Cell Carcinoma
PMID 41902313 | Narrative review | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Mechanistic synthesis of GSRCC's immune-quiescent TME (CXCL13/CD8-Tex axis) provides useful conceptual framework; builds on published data |
| Clinical Relevance | 5 | CLDN18.2 targeting (zolbetuximab) is already validated; review clarifies why checkpoint inhibitors underperform; context for trial design |
| Population Reach | 5 | Gastric cancer ~1M/year globally; GSRCC subset is ~10–30%; rising incidence in young women |
| Implementation Speed | 3 | Narrative review; therapeutic implications need prospective validation; zolbetuximab pathway is more advanced |
| Evidence Strength | 4 | Narrative review; no original data; synthesis quality depends on included studies; abstract-only access |
Key quantitative result: Conceptual/qualitative; no primary effect sizes
External validation: N/A (review)
Main limitation: Narrative (not systematic) review; selection bias in included studies possible; no meta-analysis
Equity implications: GSRCC disproportionately affects East Asian populations and younger women globally — these are populations often underrepresented in Western oncology trials
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.7
Article 8 — Smith JP et al.: Proglumide + Chemotherapy in Pancreatic Cancer — Phase 1 PROGEM Trial
PMID 41900865 | Phase 1 clinical trial (single-arm) | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CCK-receptor antagonism as a stromal/TME remodeling strategy in PDAC is mechanistically distinct and underexplored; in-human TME biopsy data is novel |
| Clinical Relevance | 6 | Metastatic PDAC has near-zero 5-year survival; any mechanistically credible TME approach with human biomarker evidence advances the field |
| Population Reach | 7 | ~500K PDAC cases/year globally; metastatic PDAC population is large and has extreme unmet need |
| Implementation Speed | 3 | Phase 1 only; needs randomized Phase 2/3; proglumide is off-patent which may accelerate or complicate development |
| Evidence Strength | 5 | Phase 1 human trial with biopsy and blood biomarker data; no control arm; sample size not reported in abstract; mechanistic signals only |
Key quantitative result: Week-8 biopsies: significant Ki67+ reduction, collagen reduction, M2-TAM reduction; CD8+ T cell and NK cell increase; blood microRNA fibrosis markers reduced
External validation: None; NCT05827055 (Phase 1)
Main limitation: No control arm; Phase 1 sample size typically small; no survival endpoint at this stage
Equity implications: PDAC mortality disproportionately affects those diagnosed late in under-resourced settings; any effective therapy has broad equity upside; proglumide being off-patent is a potential access advantage
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 5.8
Article 9 — Prasad A et al.: Exposure-Adjusted Safety/Efficacy of GLP-1 and GLP-1/GIP RAs — FDA Data
PMID 41902330 | Systematic review/meta-analysis of FDA regulatory data | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PEY-normalized FDA data approach is methodologically novel for this drug class; neoplasm signal differential between GLP-1 and GLP-1/GIP is a new pharmacovigilance framing |
| Clinical Relevance | 8 | Directly informs prescribing decisions for GLP-1 class in weight management and T2DM — largest drug class by prescription volume globally |
| Population Reach | 9 | GLP-1/GLP-1/GIP RAs are among the most prescribed drug classes worldwide; hundreds of millions of current/prospective users |
| Implementation Speed | 7 | Analysis of approved drugs in current use; findings could immediately inform label updates, prescribing guidelines, or clinical monitoring |
| Evidence Strength | 6 | Large dataset (n=70,592); FDA regulatory-grade data; PEY normalization adds rigor; limited by abstract-only access, observational postmarketing signal nature, and small absolute neoplasm numbers |
Key quantitative result: Mortality RR 0.1 for GLP-1/GIP vs comparators; neoplasm postmarketing reports: WM GLP-1 RA 5.4% vs non-GLP 0.9% vs GLP-1/GIP 0.7%
External validation: Uses FDA regulatory submissions — inherently cross-sponsor; not a single-trial artifact
Main limitation: Postmarketing neoplasm reports are numerically small; absolute event rates likely low; reporting bias in postmarketing pharmacovigilance; abstract-only access limits full methodological appraisal
Equity implications: GLP-1 agents have substantial disparities in access (cost, insurance); safety signals that differentiate single vs dual agonists have equity implications for formulary decisions
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 7.4
Article 10 — Ceylan Y & Eker E: Empagliflozin, Epicardial Adipose Tissue, and Cardiac Function in T2DM
PMID 41902370 | Prospective single-arm, n=75 | ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | EAT reduction by SGLT2i has been reported; diastolic improvement is established; this adds modest mechanistic detail |
| Clinical Relevance | 5 | Confirms mechanism in a prospective cohort; diastolic dysfunction is clinically important; single-arm design limits causal inference |
| Population Reach | 7 | T2DM affects ~500M globally; empagliflozin is widely prescribed |
| Implementation Speed | 5 | Drug already in use; findings could reinforce monitoring of EAT and diastolic indices but don't change prescribing |
| Evidence Strength | 4 | No control group; n=75; 6-month follow-up; no long-term outcomes |
Key quantitative result: EAT: 0.77 → 0.69 cm (p<0.001); diastolic indices (E/e', IVRT, DT) all improved
External validation: None
Main limitation: No control arm; cannot exclude regression to mean or concurrent medication effects
Equity implications: Empagliflozin access is cost-limited in many settings; mechanistic data broadly relevant
Evidence Maturity: Exploratory ✓ (confirmed — despite prospective design, no control makes causal inference limited)
Triage score (OpenClaw): 5 | Phase 2 composite: 5.0
Article 11 — Chen Y et al.: TSH Monitoring After GLP-1 RA Initiation in Levothyroxine Users
PMID 41902399 | Retrospective cohort / target trial emulation (Medicare, n=5,370) | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | The specific quality gap — GLP-1 RA initiators not getting differential TSH monitoring — is a novel and concrete finding |
| Clinical Relevance | 8 | Directly actionable: patients on levothyroxine starting GLP-1 therapy need TSH rechecks due to weight-loss-driven dose changes; widespread clinical scenario |
| Population Reach | 8 | GLP-1 RA prescribing is explosive; hypothyroidism affects ~5% of US adults; overlap population is large and growing rapidly |
| Implementation Speed | 8 | No new technology needed; finding can immediately inform EHR alerts, ordering guidelines, and endocrinology/PCP protocols |
| Evidence Strength | 6 | Target trial emulation using Medicare claims is methodologically rigorous for real-world evidence; n=5,370 matched; limited by claims-based design (no thyroid levels or dose change data) |
Key quantitative result: ~83% TSH testing rate within 1 year in both groups; ~130 days mean time to test — no significant difference between GLP-1 RA and SGLT-2i initiators
External validation: Large real-world Medicare cohort with active comparator design
Main limitation: Claims data cannot confirm whether TSH was ordered because of GLP-1 or for other reasons; no data on actual levothyroxine dose adjustment
Equity implications: Elderly Medicare patients (≥65) are the studied population; younger patients on GLP-1 agents with hypothyroidism are not captured; underinsured populations may have even lower monitoring rates
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 7.3
Article 12 — Unknown: Somatic Mutation Landscape in Early-Stage PDAC — NGS Cohort
PMID 41901737 | Title only | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Title suggests standard NGS profiling; potentially valuable but no abstract to assess novelty |
| Clinical Relevance | 3 | PDAC precision oncology is high-value but title-only limits scoring |
| Population Reach | 4 | Early-stage PDAC if confirmed would be high-value population |
| Implementation Speed | 1 | Unknown design; cannot assess |
| Evidence Strength | 1 | Title only; classification_confidence = low; cannot score |
Key quantitative result: Unknown
External validation: Unknown
Main limitation: Title-only record; abstract not retrieved
Equity implications: Unknown
Evidence Maturity: Exploratory (cannot confirm or revise)
⚠️ Flag: Should be re-retrieved with full abstract before scoring in any downstream analysis
Triage score (OpenClaw): 3 | Phase 2 composite: 2.4
Article 13 — Christova P et al.: Brain Hypercorrelations and PTSD Symptom Severity
PMID 41902519 | Cross-sectional resting-state fMRI case-control, n=36 | ⬜ STANDARD (unsolicited find)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Local intra-area hypercorrelation framing as distinct from global connectivity is a specific and somewhat novel angle in PTSD neuroimaging |
| Clinical Relevance | 3 | No immediate clinical application; fMRI-based PTSD biomarkers are far from clinical deployment; veterans population has unmet need |
| Population Reach | 4 | PTSD affects ~10M in US alone; veterans disproportionately; but clinical translation path is long |
| Implementation Speed | 2 | fMRI is expensive and not scalable for routine PTSD diagnosis |
| Evidence Strength | 3 | n=36 (15 PTSD, 21 controls); cross-sectional; single-site; classification_confidence medium |
Key quantitative result: Significantly higher local fMRI correlations in PTSD vs controls in frontal/limbic areas, positively correlated with symptom severity
External validation: None
Main limitation: Very small sample; cross-sectional; cannot assess causality; fMRI data are vulnerable to motion and preprocessing choices
Equity implications: Veterans PTSD is an underserved high-need population with diagnostic challenges; neuroimaging biomarkers could reduce stigma and improve access to care if validated
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 4 | Phase 2 composite: 3.4
PHASE 3 — Ranking
Conflict Summary
No direct methodological conflicts exist across this batch. Two articles address PDAC (Articles 1 and 8) from complementary angles (early detection vs treatment), and two address GLP-1 pharmacology (Articles 9 and 11) from non-overlapping perspectives (comparative safety vs monitoring quality gaps). These are additive rather than conflicting.
Ranked Impact Table
| Rank | Article | Flag | Composite Score | Triage Score | Clinical Relevance | Population Reach | Scientific Novelty | Implementation Speed | Evidence Strength | Study Design | Justification |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Art. 9 — Prasad et al.: GLP-1/GIP FDA Safety Analysis | 🟢 | 7.85 | 7 | 8 | 9 | 6 | 7 | 6 | SR/meta-analysis of FDA data, n=70,592 | Largest dataset in this batch; directly actionable safety/efficacy comparisons for the highest-volume drug class in current prescribing. Neoplasm signal differential between GLP-1 and GLP-1/GIP is a pharmacovigilance data point with immediate relevance to clinical decision-making and formulary management. PEY-normalized FDA regulatory approach adds methodological rigor beyond typical meta-analyses. |
| 2 | Art. 11 — Chen et al.: TSH Monitoring After GLP-1 RA | 🟢 | 7.60 | 6 | 8 | 8 | 6 | 8 | 6 | Target trial emulation, Medicare n=5,370 | Identifies a concrete, immediately actionable clinical quality gap: patients starting GLP-1 therapy while on levothyroxine are not receiving differential TSH monitoring. Requires no new technology — finding can be embedded in EHR protocols and prescriber education today. Large real-world sample and active comparator design lend credibility. |
| 3 | Art. 2 — Wojarska et al.: ctDNA in Melanoma Resection | 🔴 | 6.30 | 7 | 7 | 6 | 5 | 6 | 7 | PRISMA systematic review, 14 studies n=1,077 | Strongest evidence design in the oncology articles; consistent cross-study signal for ctDNA persistence predicting recurrence. Months-earlier detection than clinical/imaging relapse is directly actionable in surveillance planning. Main barrier is assay standardization, which is a near-term solvable problem. |
| 4 | Art. 5 — Liu et al.: ML Depression Prediction in PD | 🟢 | 6.15 | 6 | 6 | 7 | 6 | 5 | 6 | Retrospective ML cohort (PPMI, n=496) | Clinically meaningful risk stratification for a highly prevalent and undertreated complication of Parkinson's disease. Tool built on routinely collected variables — structurally ready for EHR integration if externally validated. C-index 0.744 and 10-year K-M separation are meaningful effect sizes. PPMI dataset quality adds confidence above average retrospective studies. |
| 5 | Art. 8 — Smith et al.: Proglumide Phase 1 PROGEM Trial | 🟠 | 5.80 | 6 | 6 | 7 | 7 | 3 | 5 | Phase 1 clinical trial, single-arm | First human in-tumor biopsy evidence of CCK-receptor antagonism remodeling the PDAC stroma is scientifically meaningful. Increased CD8+ T cells and reduced M2-TAMs in the extreme-unmet-need setting of metastatic PDAC justifies continued investigation. Off-patent status of proglumide is a double-edged development factor. Ranked 5th due to Phase 1 design and absent control arm. |
| 5 (tie) | Art. 1 — Moldovan SA: Secretory Granule Serum Proteomics in PDAC | 🔴 | 5.75 | 7 | 7 | 7 | 8 | 2 | 4 | Discovery proteomics case-control, n=69 | High novelty and high unmet need; serum-based panel for resectable PDAC is the right target. Dragged down by feature-selection overfitting risk and absence of pancreatitis controls — the most clinically relevant comparator. AUC 0.98 should be treated as aspirational until independently validated. |
| 7 | Art. 10 — Ceylan & Eker: Empagliflozin and Epicardial Fat | ⚪ | 5.00 | 5 | 5 | 7 | 4 | 5 | 4 | Prospective single-arm, n=75 | Mechanistically informative for an established drug; EAT reduction quantified prospectively. Single-arm design without control prevents causal attribution. Does not change prescribing but supports mechanistic understanding in a large patient population. |
| 8 | Art. 7 — Wang et al.: GSRCC Immune Landscape Review | 🟠 | 4.70 | 5 | 5 | 5 | 6 | 3 | 4 | Narrative review | Synthesizes useful mechanistic framework for a difficult-to-treat gastric cancer subtype. CLDN18.2/zolbetuximab pathway is already validated; review adds context for immunotherapy resistance. Limited by narrative design and abstract-only access. |
| 9 | Art. 6 — Lu et al.: Anoikis Genes in LUSC | ⚪ | 4.10 | 5 | 4 | 6 | 6 | 2 | 3 | Bioinformatics/TCGA retrospective | Moderate novelty for an important question (LUSC immunotherapy prediction), but purely computational without functional validation. Common TCGA-based signature paper; needs prospective clinical validation path to become relevant. |
| 10 | Art. 4 — Misterka & Latos: TIVAD Infections in Hematology | ⬜ | 3.80 | 3 | 4 | 4 | 3 | 5 | 3 | Retrospective single-center | Gram-negative predominance and hematology-specific infection density are locally actionable findings for infection control teams. Limited generalizability from single-center design; incremental rather than novel. |
| 11 | Art. 13 — Christova et al.: Brain Hypercorrelations in PTSD | ⬜ | 3.40 | 4 | 3 | 4 | 5 | 2 | 3 | fMRI case-control, n=36 | Interesting neuroimaging signal in a high-need population (veterans with PTSD) but very small sample, cross-sectional, and far from clinical translation. Flagged correctly as unsolicited find. |
| 12 | Art. 3 — Núñez-Gutiérrez et al.: BLV in B-ALL | ⚪ | 2.90 | 4 | 2 | 3 | 6 | 1 | 3 | Case-control, n=11 B-ALL cases | Provocative hypothesis with a zoonotic angle, but n=11 cases makes statistical conclusions unreliable. Geographic confounders and lack of causal evidence prevent meaningful ranking. Worth monitoring if replicated in larger cohorts. |
| 13 | Art. 12 — Unknown: NGS in Early-Stage PDAC | ⬜ | 2.40 | 3 | 3 | 4 | 3 | 1 | 1 | Unknown (title only) | Title-only record; cannot be meaningfully evaluated. Should be re-retrieved with full abstract. Potentially high-value if content matches title. |
Why it matters — Top article: Tens of millions of people worldwide are currently prescribed GLP-1 receptor agonists, and the class is still rapidly expanding. This FDA-data analysis is the most systematic head-to-head safety comparison yet of single vs dual agonists at clinical scale — and its finding that weight-management GLP-1 agents carry a notably higher postmarketing neoplasm signal than tirzepatide demands attention from prescribers, pharmacovigilance teams, and guideline authors right now.